We want to discover, develop and successfully market innovative products to cure diseases,
to ease suffering and to enhanc...
”
2004 Highlights
Double-digit Pharmaceuticals growth – Pharmaceuticals division outpaces the global market with double-di...
Upcoming SlideShare
Loading in...5
×

Novartis Corporation

964

Published on

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
964
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
19
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Transcript of "Novartis Corporation"

  1. 1. We want to discover, develop and successfully market innovative products to cure diseases, to ease suffering and to enhance the quality of life. We also want to provide a shareholder return that reflects outstanding performance and to adequately reward those who invest ideas and work in our company. Novartis Corporation Novartis World Headquarters: Basel, Switzerland Novartis CEO: Daniel Vasella, MD 2004 Worldwide Sales: Group net sales increased 14 percent to $28.2 billion Pharmaceutical net sales rose 15 percent Consumer Health net sales gained 10 percent 2004 Net Income: Grew 15 percent to $5.8 billion Number of Novartis Employees: 81,400 worldwide, operating in over 140 countries 2004 R&D Investment: $4.2 billion Stock Exchange Listing: NVS; earnings per share USD 2.36 (+16%) Major Divisions Pharmaceuticals – therapeutic medicines, including Zelnorm® and Elidel® , in the following areas: cardiovascular & metabolism, neuroscience, respiratory & dermatology, AGBHI (arthritis, gastrointestinal, bone, hormone replace- ment therapies, infectious diseases), oncology & hematology, transplantation & immunology and ophthalmics Sandoz – generic pharmaceuticals Consumer Health – business units include: • Over the Counter (OTC) – self-medication products, including Lamisil® and Theraflu® , for the in-home treatment and prevention of medical conditions and ailments • Animal Health – treatments and vaccines, including Interceptor® and Vira Shield® , for the well-being of companion animals and the health and productivity of farm animals • Medical Nutrition – a complete range of enteral nutrition, medical food products and services, including Boost® • Infant and Baby – infant and toddler nutrition, care and wellness products, including Gerber baby and toddler food • CIBA Vision – optical and ophthalmic products and services, including O2Optix™ and Night&Day™ contact lenses and lens care products
  2. 2. ” 2004 Highlights Double-digit Pharmaceuticals growth – Pharmaceuticals division outpaces the global market with double-digit net sales growth of 15 percent. Global market shares increased to 4.5 percent from 4.42 percent. Positive margin development – Operating income expands faster than net sales as operating margin expands 0.8 percentage points, to 28.4 percent of net sales. Strong organic growth and productivity initiatives continue to support improved profitability. Five blockbuster brands – Five top-ranked medicines in key market segments achieve net sales of more than USD 1 billion in 2004, led by Diovan® , Gleevec™ /Glivec® and Zometa® . Novartis is on track to deliver seven blockbusters by 2008 through dynamic growth of young product portfolio. Cardiovascular and oncology driving growth – Novartis ranks as one of the largest and fastest-growing pharmaceutical companies in oncology, while Diovan® and Lotrel® are leading medicines in the fight against high blood pressure. Highly rated pipeline – Strategically balanced development portfolio focuses on promising therapeutic areas, both in terms of innovative compounds and new indications for in-market products. Strong patent position – Novartis is consistently ranked as having one of the industry’s lowest exposures to competition from generics during the next five years, reflecting the launch of 13 new medicines in the United States since 2000. Research – Novartis Institutes of BioMedical Research doubles scientific staff at Cambridge headquarters, with emphasis on biology of diseases with high unmet medical need, and strong commitment to external collaboration and strategic partnerships. Corporate citizenship – In 2004, Novartis was able to contribute $570 million to patients in need through access to medicine programs. Key Worldwide Products Description Diovan® /Co-Diovan® Used in the treatment of hypertension Gleevec™ /Glivec® Used in the treatment of Chronic Myeloid Leukemia (CML) and Gastrointestinal Stromal Tumors (GIST) Neoral/Sandimmun® Immunosuppressive agent for transplantations Lamisil® Antifungal agent Zometa® Used in the treatment of bone metastasis in a variety of tumor types Lotrel® Used in the treatment of hypertension Lescol® Used in the treatment of atherosclerosis vascular disease Sandostatin Lescol® /LAR® Used to reduce blood levels of growth hormone and IGF-I in acromegaly patients Voltaren® Nonsteroidal anti-inflammatory, antirheumatic agent Cibacen® /Lotensin® ACE inhibitor, antihypertensive agent Record results reflect our emphasis on sustainable, organic growth, a product of our constant innovation strategy and the skills and commitment of over 81,000 associates worldwide. Novartis CEO Daniel Vasella “

×